Birrer Shares Perspective on Folate Receptor Alpha-Targeting Agents in Ovarian Cancer

Published: Wednesday, Apr 17, 2019
Michael Birrer,
MD, PhD

Michael Birrer, MD, PhD
Folate receptor alpha (FRα) is an active area of investigation in the ovarian cancer paradigm, as it is highly overexpressed in approximately 60% of patients with high-grade, serous ovarian cancer, explained Michael Birrer, MD, PhD.

 
What are some common knowledge gaps in ovarian cancer when it comes to these newer approaches in research?

 
I think we still have a problem with the upfront treatment. We probably cure about 15%, but that number hasn’t changed in 35 years. This is why [the] SOLO-I [trial] is so exciting, in that the PFS curve is pretty flat at the end and had not even reached median PFS, so that is the kind of improvement we need to see more of, and, of course, ultimately stratifying patients according to who will really benefit from the treatment versus toxicity is really important. The other area [in which there] is still an unmet need is the effective treatment of platinum-resistant disease, which is on the other end of the spectrum. Once patients recur, they are incurable, and most tumors will eventually become platinum-resistant. [Patients with] platinum-resistant tumors have a median overall survival of about 11 months and a median PFS of about 6 months.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x